Abstract
New oral contraceptive (OC) formulations feature shorter hormone-free intervals or continuous use of hormones (Journal Watch Women’s Health Aug 31 2006). In a manufacturer-sponsored, open-label North American trial, investigators assessed the efficacy and safety of a continuous OC formulation combining 20 μg ethinyl estradiol and 90 μg levonorgestrel (similar to Alesse and Levlite). The study OC was supplied in 28-day packs …
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
